Compare PLBY & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLBY | CALC |
|---|---|---|
| Founded | 1953 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.6M | 88.3M |
| IPO Year | N/A | N/A |
| Metric | PLBY | CALC |
|---|---|---|
| Price | $1.85 | $6.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 1.3M | 103.2K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,510,000.00 | N/A |
| Revenue This Year | $4.97 | N/A |
| Revenue Next Year | $8.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $1.42 |
| 52 Week High | $2.53 | $7.20 |
| Indicator | PLBY | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 50.31 | 71.29 |
| Support Level | $1.81 | $5.55 |
| Resistance Level | $1.94 | $7.20 |
| Average True Range (ATR) | 0.13 | 0.69 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 26.61 | 86.15 |
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.